[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634749":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":44,"collaborators":10,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8,12,15,18],{"label":9,"type":10,"description":11,"interventionNames":10},"Inclisiran Cohort",null,"Patients receiving inclisiran injection(s).",{"label":13,"type":10,"description":14,"interventionNames":10},"Evolocumab Cohort","Patients receiving evolocumab injection(s).",{"label":16,"type":10,"description":17,"interventionNames":10},"Alirocumab Cohort","Patients receiving alirocumab injection(s).",{"label":19,"type":10,"description":20,"interventionNames":10},"Pooled Anti-PCSK9-mAb Cohort","Patients receiving anti-PCSK9-mAbs either evolocumab or alirocumab.",[22],{"name":23,"affiliation":23,"role":24},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":10,"email":29},"CONTACT","+41613241111","novartis.email@novartis.com",{"name":23,"role":27,"phone":10,"phoneExt":10,"email":10},[32],{"facility":5,"status":33,"city":34,"state":10,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":10},"RECRUITING","Basel","CH-4056","Switzerland","CH",{"type":39,"coordinates":40},"Point",[41,42],7.57327,47.55839,{"lat":42,"lon":41},{"type":45,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100634749","a-real-world-study-of-long-term-adherence-and-persistence-to-inclisiran-evolocumab-and-alirocumab-100634749",false,"NCT07543731","A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab","Real-World Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab in Italy","VICTORION-LEAP","Inclusion criteria:\n\n* A first ever prescription of injection of inclisiran, evolocumab, or alirocumab during the identification period.\n* Age ≥18 years at index date.\n* With at least 12 months data availability prior to index date.\n\nExclusion criteria:\n\n• Patients who received either evolocumab or alirocumab as their index study drug and who were dispensed the other anti-PCSK9-mAb (alirocumab and evolocumab respectively) before the identification period.","ALL","18 Years","99 Years",{"count":58,"type":59},5995,"ESTIMATED","OBSERVATIONAL","This study aims to evaluate the long-term adherence and persistence to inclisiran and anti-proprotein convertase subtilisin\u002Fkexin type 9 (PCSK9) monoclonal antibodies (mAbs) in real-world clinical practice.",[63,64,65],"Cardiovascular Diseases","Atherosclerotic Cardiovascular Disease","Hypercholesterolemia, Familial",[67,68,69,70,71,72],"Real-world","Retrospective","Adherence","Persistence","Long-term","PCSK9i","2026-07-14",{"date":75,"type":76},"2026-07-15","ACTUAL",{"date":78,"type":76},"2026-04-02",{"date":80,"type":59},"2026-10-30",{"name":23,"class":6},1]